| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Werewolf Therapeutics, Inc.$0.35
-0.01 (-1.39%)
D 39Pipeline Score Undervalued Pharma · Commercial
Market Cap
21.56 M
EPS
-1.21
P/E Ratio
-
Value Trade
160.24 K
SEC Financials
Q1 2026Dilution Risk
40%R&D Expenses
8.18 M
Operating CF
-10.60 M
Total Assets
58.02 M
Total Liabilities
45.82 M
Equity
12.20 M
D/E Ratio
12,345
-17.85 %
Week
-51.42 %
1 Month
-38.81 %
3 Month
-47.43 %
6 Month
-96.38 %
5 Year
-97.56 %
All Time
Cash Data
Cash Position
46.45 M
Monthly Burn
3.53 M
Runway
11.6 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
1.27 M
52 Week Range
0.40 - 2.38
% held by Insiders
17.5 %
% held by Institutions
19.03 %
Enterprise Value
12.76 M
Total Shares
48.62 M
Short %
2.41 %
Float Shares
36.17 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Werewolf Therapeutics, Inc.
234Total events
6Upcoming
19Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 6
Event history 228
May 7, 2026
▲Partnership / LicenseJZP898Corporate
Asset purchase agreement with Jazz Pharmaceuticals for JZP898
IFN programsource ↗
May 6, 2026
▲Debt Royalty FinancingCorporate
Repayment of loan and security agreement with K2 HealthVentures
Mar 27, 2026
◆Pipeline PrioritizationCorporate
Initiated process to explore strategic alternatives including sale, merger, or licensing
Feb 24, 2026
◆Pipeline PrioritizationCorporate
Company announces exploration of strategic alternatives including sale, merger, or licensing
Q1 2026
◆Topline ReadoutWTX-124Clinical Data
Final Phase 1/1b data anticipated in 1H26
advanced/metastatic cancerssource ↗
Q1 2026
◆Topline ReadoutWTX-330Clinical Data
Phase 1b/2 update anticipated in 1H26
advanced/metastatic cancerssource ↗
Q1 2026
Q1 2026
●Primary CompletionWTX-330Trial
Completion of Part A of Phase 1b/2 clinical trial
solid tumorssource ↗
Drug Pipeline Intelligence
D39
Pipeline Score $27M
Pipeline ValueUndervalued
Valuation Signal2
Drugs Scored4.2x
rNPV / MCap Top 56%
Micro Cap (rank 399 of 905)
Percentile RankWerewolf Therapeutics, Inc. faces pipeline headwinds (39/100), with $2.5B risk-adjusted pipeline value, led by WTX-124 in Metastatic Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WTX-124 Small molecule | Metastatic Solid Tumor | Phase 1 | NCT05479812 | 5% | $1.6B | ACTIVE NOT_RECRUITING | 150 | AVERAGE | C (41) | Jul 31, 2026 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
WTX-124 | renal cell carcinoma | — | 2025-07-09 | |||
WTX-124 | renal cell carcinoma | — | 2025-07-09 | |||
WTX-124 | renal cell carcinoma | — | 2025-07-09 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HOWL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
HOWL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
HOWL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
HOWL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
HOWL Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
HOWL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
HOWLWerewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates - Company continues to evaluate strategic options to maximize shareholder value - Watertown, Mass.
Werewolf Therapeutics has released its first-quarter financial results for 2026, demonstrating a reduced net loss of $13.5 million compared to $18.1 million in the prior year. The company is actively exploring strategic options aimed at maximizing shareholder value, including a successful asset purchase agreement with Jazz Pharmaceuticals for the JZP898 program. However, its cash position has declined to $46.5 million from $57.1 million in the last quarter. Ongoing uncertainties surrounding the development of its product candidates were also noted.
Read more →HOWLWerewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Werewolf Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting a strategic evaluation process to maximize stockholder value. The company has engaged Piper Sandler as a financial advisor for potential transactions. Financially, the company showed a decrease in both research and development expenses and net loss compared to 2024.
Read more →HOWLWerewolf Therapeutics Announces Plan to Explore Strategic Alternatives
Werewolf Therapeutics announced plans to explore various strategic alternatives aimed at maximizing stockholder value. The company has engaged Piper Sandler & Co. as its financial advisor for this process. Potential options include a sale of the company, mergers, or collaborations, although no specific timeline or guarantees for success have been provided.
Read more →HOWLWerewolf Therapeutics Announces Pipeline and Business Updates
Werewolf Therapeutics has announced significant advancements in its clinical pipeline, particularly for its candidates WTX-124 and WTX-330. Initial data from the WTX-124 Phase 1b trial indicates a 30% overall response rate as a monotherapy in a specific subset of melanoma patients. Additionally, Phase 1b/2 data for WTX-330 suggests promising tolerability and antitumor activity. The company is focused on securing strategic partnerships for further development and anticipates completing trials for both candidates by mid-2026.
Read more →HOWLCorporate Presentation December 2025 1 | 2025 WEREWOLF THERAPEUTICS 2025 WEREWOLF THERAPEUTICS Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements that involve subst
Werewolf Therapeutics presented forward-looking statements regarding its pipeline and future operations, highlighting key product candidates including WTX-124 and WTX-330, which are in clinical development. The presentation emphasized the company's innovative PREDATOR platform, showcasing its potential to address limitations in existing cancer immunotherapies. Strategic partnerships are being sought to bolster drug development, with notable preliminary clinical trial data suggesting promising safety and efficacy outcomes. However, the company acknowledges the inherent uncertainties of clinical trials and the need for regulatory approvals.
Read more →HOWLWerewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
Werewolf Therapeutics presented promising preclinical data at the SITC 40th Annual Meeting, showcasing its PREDATOR platform. The data highlighted a sequential dosing regimen that enhances antitumor activity while minimizing systemic toxicities. Additionally, the first real-time pharmacokinetic data for WTX-124 confirmed its selective activation in tumor environments, supporting ongoing clinical trials.
Read more →HOWLWerewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Werewolf Therapeutics reported its third quarter 2025 financial results, highlighting advancements in its clinical programs, particularly WTX-124 and WTX-330. The company plans to provide updates on these programs and its first INDUCER candidate, WTX-1011, later in the fourth quarter. WTX-124 has received Fast Track Designation, indicating progress towards registration-enabling trials.
Read more →HOWLWerewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
Werewolf Therapeutics has received Fast Track Designation from the FDA for WTX-124, an investigational therapy aimed at treating advanced cutaneous melanoma. This designation is intended to expedite the development of drugs addressing serious unmet medical needs. The company is currently evaluating WTX-124 in a Phase 1/1b clinical trial, with preliminary data expected soon.
Read more →HOWLWerewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
Werewolf Therapeutics, Inc. announced the presentation of three posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting, scheduled for November 5-9, 2025. The posters will showcase research on their conditionally activated therapeutics aimed at enhancing antitumor activity while minimizing toxicity. This highlights the company's commitment to advancing cancer treatment through innovative approaches.
Read more →HOWLWerewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
Werewolf Therapeutics will participate in the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. CEO Daniel J. Hicklin and CMO Randi Isaacs will engage in a fireside chat to discuss the company's innovative therapies. The event will be available via live webcast and archived for 90 days.
Read more →HOWLWerewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - WTX-124 Phase 1 1b clinical trial on track for interim data readout in the fourth quarter of 2025, including patients in
Werewolf Therapeutics reported its financial results for Q2 2025, highlighting the positive progress of the WTX-124 Phase 1 1b clinical trial, which is set for interim data readout in Q4 2025. The company plans to engage the FDA to discuss potential registrational pathways for WTX-124 in advanced cutaneous melanoma. Additionally, Werewolf introduced WTX-1011, a new T-cell engager candidate for treating prostate cancer. However, the company's financial outlook shows a net loss of $18 million and a reduction in cash reserves over the last quarter.
Read more →HOWLWerewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
Werewolf Therapeutics will present at the KidneyCAN 7th Annual Kidney Cancer Research Summit on July 17-18, 2025. Dr. Randi Isaacs will discuss the company's WTX-124, a tumor-activated IL-2 INDUKINE molecule aimed at enhancing immune response in renal cell carcinoma. The presentation will highlight early clinical findings and the ongoing national trials for advanced or metastatic RCC.
Read more →HOWLWerewolf Therapeutics to Participate in the BIO International Convention
Werewolf Therapeutics will participate in the BIO International Convention from June 16-19, 2025, where Dr. Randi Isaacs will discuss conditionally activated biologics. This innovative approach aims to enhance anti-tumor activity while reducing toxicity. The company also launches the 'Full Moon Moment' initiative to promote its clinical trials, including the promising WTX-124 molecule.
Read more →HOWLWerewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
Werewolf Therapeutics, Inc. will participate in the Jefferies Global Healthcare Conference from June 3-5, 2025. CEO Daniel J. Hicklin and CMO Randi Isaacs will engage in a fireside chat on June 5 at 4:20 PM EDT. The event will be accessible via a live webcast and archived for 90 days.
Read more →HOWLWerewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit
Werewolf Therapeutics, Inc. announced its participation in the 6th Annual Cytokine-Based Drug Development Summit, where Sameer Chopra, M.D., Ph.D., will present data on their IL-2 and IL-12 INDUKINE molecules. The presentation will focus on the successful validation of these immunotherapies in clinical trials. Werewolf's approach aims to selectively activate treatments in the tumor microenvironment, potentially improving therapeutic outcomes for cancer patients.
Read more →HOWLWerewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - WTX-124 Phase 1 1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year
Werewolf Therapeutics has reported its financial results for the first quarter of 2025 and provided a business update. The company is on track in its WTX-124 Phase 1 1b trial, with plans for interim data presentation and FDA engagement later this year. Additionally, the WTX-330 Phase 1b 2 trial has commenced, aiming to optimize the therapeutic exposure in the tumor microenvironment. Despite a net loss reported for the quarter, Werewolf's cash guidance suggests operational effectiveness until late 2026 as it advances its clinical programs and pipeline development.
Read more →HOWLWerewolf Therapeutics to Participate in Upcoming Investor Conferences
Werewolf Therapeutics, Inc. announced its participation in two upcoming investor conferences in May 2025. The events include the Citizens Life Sciences Conference on May 8 and the Bank of America Securities Health Care Conference on May 14. Management will be involved in fireside chats at both conferences, providing insights into the company's innovative approach in developing therapeutic solutions using their proprietary PREDATOR® platform. The company's work focuses on conditionally activated therapeutics for cancer and immune-mediated conditions.
Read more →HOWLWerewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
Werewolf Therapeutics has presented new preclinical data on its IL-10 INDUKINE molecule, WTX-921, for treating Inflammatory Bowel Disease (IBD) at the AAI Annual Meeting. The results show that WTX-921 effectively reduced inflammation in a mouse model, offering insights into its mechanism of action. The molecule is engineered to specifically target inflamed colon tissue while minimizing off-target effects associated with systemic IL-10 therapy. This advancement could provide significant benefits for IBD patients, enhancing treatment efficacy while reducing adverse reactions.
Read more →HOWLWerewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
Werewolf Therapeutics has appointed Steven Bloom as its Chief Business Officer, bringing over 35 years of experience in the life sciences sector. Bloom's expertise is anticipated to enhance the company's corporate strategy at a pivotal time, with upcoming clinical trial data from WTX-124 expected to inform regulatory discussions. Werewolf continues to advance its PREDATOR platform, while Bloom is set to leverage his previous experiences to guide the organization in business development and growth initiatives. The company remains focused on pioneering immune-mediated cancer treatments with its innovative therapeutic technologies.
Read more →HOWLWerewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Werewolf Therapeutics, Inc. announced that its executives will present at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025. This presentation will highlight the company's innovative approach to developing conditionally activated therapeutics aimed at enhancing immune response for cancer treatment. The event underscores Werewolf's commitment to advancing its clinical candidates, WTX-124 and WTX-330, designed to selectively activate in the tumor microenvironment. A live webcast and subsequently archived playback will be available for those interested in the presentation.
Read more →HOWLWerewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1 1b clinical trial evaluating WTX-124 a
Werewolf Therapeutics has reported its financial results for Q4 and the full year 2024, highlighting significant progress in its clinical trials. The company expects full enrollment in dose-expansion arms for their WTX-124 melanoma therapy by the end of 2025 and plans to discuss registrational pathways with the FDA. However, the company also reported an increased net loss and a significant drop in collaboration revenue year-over-year. Overall, the data suggests a focus on advancing their clinical development amidst financial challenges.
Read more →HOWLWerewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
Werewolf Therapeutics, Inc. will present at the 2025 Leerink Partners Global Biopharma Conference in Miami from March 10-12, 2025. The company's leadership, including CEO Daniel J. Hicklin and CMO Randi Isaacs, will engage in a fireside chat on March 11, 2025. Werewolf specializes in developing conditionally activated therapeutics aimed at treating cancer and other immune-mediated conditions through its proprietary PREDATOR® platform.
Read more →HOWLWerewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
Werewolf Therapeutics, Inc. announced the appointment of Anil Singhal, Ph.D., to its board of directors, enhancing its leadership with his extensive experience in oncology. Dr. Singhal, who is the CEO of Trishula Therapeutics, expressed enthusiasm for advancing Werewolf's novel INDUKINE molecules for cancer treatment. Concurrently, the company noted that Derek DiRocco will resign from the board at the upcoming annual meeting. This leadership change comes at a pivotal time in Werewolf's development of innovative therapies aimed at stimulating the immune system.
Read more →HOWLWerewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
Werewolf Therapeutics announced key updates regarding its clinical programs and strategic outlook for 2025. It expects interim data from its WTX-124 trials in monotherapy and combination settings in 2025, which will inform regulatory discussions. Additionally, the company plans to initiate Phase 1/2 trials for WTX-330, targeting immunotherapy-resistant cancers. Their financial position remains robust, projected to sustain operations through at least mid-2026.
Read more →HOWLWerewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
Werewolf Therapeutics, Inc. announced its participation in the 7th Annual Evercore ISI HealthCONx Healthcare Conference. Executives Daniel J. Hicklin, Ph.D., and Randi Isaacs, M.D. will host a fireside chat on December 5, 2024. The conference takes place from December 3-5 in Miami, Florida, highlighting the company's advancements in conditionally activated therapeutics for cancer treatment. The live webcast of the chat will be available for investors and others interested in the company's progress.
Read more →HOWLDelivering the Power of Immunotherapy CORPORATE PRESENTATION | November 2024 1 | 2024 WEREWOLF THERAPEUTICS Cautionary Statements This presentation contains forward-looking statements that involve substantial risks and u
Werewolf Therapeutics presented its corporate strategies and drug development plans for November 2024, focusing on its innovative cytokine therapies. The company aims to harness the potential of its next-generation products, particularly emphasizing the pipeline's promising candidates such as WTX-124. However, the presentation also outlines significant risks and uncertainties associated with drug development. The company is positioned well financially, with sufficient cash runway projected to support their operations through 2026.
Read more →HOWLWerewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Werewolf Therapeutics presented both preclinical and interim phase 1 clinical trial data at the 2024 SITC Annual Meeting. The findings underscore the potential of WTX-330, a tumor-activated IL-12 prodrug, showcasing a favorable tolerability profile and encouraging signs of efficacy in patients with treatment-resistant solid tumors. Additionally, preclinical data highlighted the antitumor activity of INDUKINE molecules. The company plans to optimize further trials based on these promising results, with enrollment for a Phase 1/2 study expected in early 2025.
Read more →HOWLWerewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to
Werewolf Therapeutics reported its third quarter 2024 financial results, highlighting progress in clinical trials for its candidates WTX-124 and WTX-330. Interim data for WTX-330 is to be presented at the SITC Annual Meeting, showcasing emerging tolerability and clinical activity. Additionally, the company introduced WTX-921, targeting inflammatory diseases, and updated its cash guidance to ensure funds through at least the second quarter of 2026. However, the company reported a net loss that has increased compared to the previous year, raising concerns about financial stability.
Read more →HOWLWerewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
Werewolf Therapeutics has announced the addition of WTX-921, a novel IL-10 INDUKINE candidate, to its pipeline aimed at addressing inflammatory diseases, particularly Inflammatory Bowel Disease (IBD). This development signifies a strategic expansion of their innovative PREDATOR platform, which has previously shown promise in oncology applications. With IBD being a chronic condition characterized by considerable unmet needs, the company aims to leverage its unique drug design approach to improve treatment outcomes for patients. The advancement underscores Werewolf's commitment to exploring new therapeutic areas beyond oncology.
Read more →HOWLWerewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Werewolf Therapeutics, Inc. has announced that it will present two posters at the Society for Immunotherapy of Cancer’s 39th Annual Meeting scheduled for November 6-10, 2024, in Houston, Texas. The posters will highlight data regarding their INDUKINE™ molecules and interim results from a Phase 1 study of their tumor-activated IL-12 prodrug, WTX-330. These presentations underscore the company's commitment to developing innovative cancer treatments through its proprietary therapeutic platforms.
Read more →HOWLWerewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Werewolf Therapeutics, Inc. has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Daniel J. Hicklin, Ph.D., and Randi Isaacs, M.D. will engage in a fireside chat on September 10, 2024. The conference runs from September 9-11, 2024, in New York City. The company focuses on developing therapeutics that activate the immune system specifically within the tumor microenvironment to aid cancer treatment.
Read more →HOWLWerewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - Positive data from ongoing Phase 1 1b clinical trial of WTX-124 presented at American Society of Clinical Oncology (ASCO)
Werewolf Therapeutics reported positive interim data from its ongoing Phase 1b clinical trial of WTX-124 at the ASCO meeting, showing clinical activity and tolerable doses in patients. The company is also progressing WTX-330, demonstrating promising exposure levels and initial efficacy. Despite these positive developments, Werewolf’s financial report indicates a significant net loss and decreased collaboration revenue from the previous year. The company maintains a strong cash position but faces challenges in its revenue stream.
Read more →HOWLWerewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma - Data demonstrate
Werewolf Therapeutics has announced promising initial results from its Phase 1 clinical trial evaluating WTX-330, an interleukin-12 therapy, in patients with advanced cancers. The data indicates encouraging safety and efficacy, with notable exposure levels and signs of clinical activity. Early results have shown an unconfirmed partial response in a metastatic melanoma patient. Officials from Werewolf express optimism about the future development of WTX-330, which could address challenges faced by patients resistant to standard immunotherapies.
Read more →HOWLWerewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors - WTX-124 was shown to be clinically active and generally well-
Werewolf Therapeutics announced positive results from its ongoing Phase 1/1b trial of WTX-124, which is being evaluated as a monotherapy and in combination with pembrolizumab for solid tumors. Data presented at the 2024 ASCO Annual Meeting highlighted clinical activity, with notable responses in patients who were previously treated with immune checkpoint inhibitors. The recommended dose for expansion has been selected, and enrollment for additional arms is underway. The findings suggest potential for WTX-124 as a best-in-class therapy with fewer toxicities compared to traditional high-dose IL-2 treatments.
Read more →HOWLWerewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
Werewolf Therapeutics announced promising data from its Phase 1/1b clinical trial for WTX-124, a novel Interleukin-2 therapy, highlighting its clinical activity in patients resistant to checkpoint inhibitors. The drug showed three objective responses, one being a durable complete response, and was generally well-tolerated both as monotherapy and in combination with pembrolizumab. Following these results, the company has opened expansion arms for further testing in specific cancer types while continuing to refine dosing strategies. Detailed results will be shared during a webcast on June 3, 2024, after their presentation at the ASCO Annual Meeting.
Read more →HOWLWerewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 6, 2024. CEO Daniel J. Hicklin and CMO Randi Isaacs will represent the company during the event. The conference takes place in New York City from June 4-6, 2024. Werewolf is known for its conditionally activated immunotherapies aimed at treating cancer, specifically utilizing their proprietary PREDATOR™ platform.
Read more →HOWLWerewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
Werewolf Therapeutics has announced upcoming presentations of updated clinical data on WTX-124 from its Phase 1/1b trial. The trial evaluates WTX-124 as both a monotherapy and in combination with pembrolizumab for patients with checkpoint therapy-resistant solid tumors. Initial findings indicate WTX-124 is well tolerated and shows clinical activity. Further details will be presented at the ASCO Annual Meeting from May 31 to June 4, 2024, in Chicago, Illinois.
Read more →HOWLWerewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - Company to present an update of its ongoing monotherapy and combination Phase 1 1b trial of WTX-124 in advanced or metasta
Werewolf Therapeutics reported its financial results for Q1 2024 and provided an update on its clinical programs. The company is set to present interim clinical data for its lead candidates WTX-124 and WTX-330 at upcoming ASCO and other meetings. Notably, Werewolf has extended its cash runway to the first quarter of 2026, although it reported an increased net loss compared to the prior year. Collaboration revenue has also decreased significantly during this period, indicating potential financial challenges ahead.
Read more →HOWLWerewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Werewolf Therapeutics has announced that an abstract detailing their ongoing Phase 1/1b study of WTX-124 has been accepted for presentation at the 2024 ASCO Annual Meeting. This study involves investigating WTX-124, a conditionally activated interleukin 2 molecule, in patients with advanced or metastatic solid tumors following checkpoint inhibitor therapy. The presentation is scheduled for June 1, 2024. This update indicates progress in Werewolf's effort to leverage innovative immunotherapies for cancer treatment.
Read more →HOWLWerewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
Werewolf Therapeutics announced the presentation of preclinical data at the AAI Annual Meeting, showcasing its IL-10 INDUKINE molecules for treating Inflammatory Bowel Disease (IBD). The findings indicate that these molecules can activate locally in inflamed colonic tissues, offering a novel therapeutic strategy. This represents an extension of Werewolf's PREDATOR platform from cancer treatment into immunology and inflammation. The data highlights the potential effectiveness in addressing issues faced by patients who do not respond to current IBD therapies.
Read more →HOWLWerewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
Werewolf Therapeutics presented promising preclinical data for its cytokine therapeutics WTX-518 and WTX-712 at the AACR 2024 Annual Meeting. WTX-518 showed complete tumor regression in animal models, while WTX-712 demonstrated strong anti-tumor effects through unique immune activation pathways. Both candidates are designed to selectively activate in the tumor microenvironment and could provide new options for treating refractory cancers. The findings highlight the potential innovations in the company's therapeutic strategies against cancer.
Read more →HOWLWerewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
Werewolf Therapeutics announced that it will present data on its PREDATOR platform at the AAI Annual Meeting scheduled for May 3-7, 2024. The company aims to highlight the platform's potential in treating immunology-based diseases in addition to its primary focus on oncology. This marks an important step for Werewolf as it seeks to validate its approach and engage with experts in the immunology field. The specific poster presentation will focus on conditionally active IL-10 INDUKINE molecules for inflammatory bowel disease.
Read more →HOWLWerewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - Additional monotherapy dose-escalation data from ongoing Phase 1 1b clinical trial of WTX-124 expected to b
Werewolf Therapeutics reported its financial results for Q4 and full year 2023, highlighting significant advancements in its clinical pipeline. The company anticipates presenting additional data from its WTX-124 clinical trials in the first half of 2024 and expects to initiate dose expansion arms. Financial updates reveal a strong cash position, sufficient to support operations through at least Q2 2025, despite a decrease in collaboration revenue. The recent retirement of a key executive may also impact the company moving forward.
Read more →HOWLWerewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
Werewolf Therapeutics, a biopharmaceutical company focused on developing immune-stimulating therapeutics for cancer, announced their participation in the 2024 Leerink Partners Global Biopharma Conference. Daniel J. Hicklin, Ph.D., and Randi Isaacs, M.D. will represent the company in a fireside chat on March 13, 2024. The conference is set to take place in Miami, Florida, from March 11-13, 2024. Werewolf is known for its proprietary PREDATOR platform and is progressing with product candidates like WTX-124 and WTX-330.
Read more →HOWLWerewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
Werewolf Therapeutics has announced that it will present abstracts at the AACR Annual Meeting 2024, focused on innovative cancer therapies. The abstracts include data on WTX-712, an IL-21 INDUKINE molecule that induces a strong anti-tumor response, and WTX-518, an IL-18 pro-drug activated within tumor microenvironments. These presentations will take place on April 9, 2024, in San Diego, California, demonstrating the company's ongoing commitment to advancing cancer treatment through conditionally activated therapeutics.
Read more →HOWLWerewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook - Prioritizing development of wholly owned clinical assets, WTX-124 and WTX-330; key updates from both INDUKINE TM programs anticipated
Werewolf Therapeutics provided a strategic business update, emphasizing the development of their clinical assets, WTX-124 and WTX-330, for the upcoming year. The company anticipates releasing updated interim monotherapy data from WTX-124 in the first half of 2024 and dose-escalation data from WTX-330 in the second quarter of 2024. Additionally, Werewolf's financial outlook indicates sufficient cash to fund operations through at least the first quarter of 2025. The firm plans to explore partnerships to extend its innovative therapeutic approach beyond oncology.
Read more →HOWLWerewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
Werewolf Therapeutics has appointed Dr. Michael B. Atkins to its Board of Directors. Dr. Atkins is a distinguished oncologist with a wealth of experience in cancer immunotherapy research. His role is expected to provide invaluable insights as the company develops its INDUKINE therapeutics, WTX-124 and WTX-330. His background includes significant contributions to melanoma and kidney cancer research, positioning the company for strategic growth in innovative cancer therapies.
Read more →HOWLWerewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
Werewolf Therapeutics, Inc. has announced that its President and CEO, Daniel J. Hicklin, and Chief Medical Officer, Randi Isaacs, will present at the Evercore ISI HealthCONx Conference in Miami, Florida, on November 29, 2023. The company is recognized for pioneering therapeutics that activate the immune system for cancer treatment, utilizing its proprietary PREDATOR™ platform to improve therapeutic outcomes. Their key product candidates, WTX-124 and WTX-330, target solid tumors and aim to enhance the efficacy of conventional therapies. A live webcast of the presentation will be made available for investors and interested parties.
Read more →HOWLWerewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update - Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1 1b clinical trial provide compell
Werewolf Therapeutics reported its third-quarter financial results alongside a business update, highlighting promising preliminary data from the WTX-124 clinical trial. The data suggests WTX-124 has a favorable safety profile and shows early signs of anti-tumor activity in patients. Additionally, the company announced the introduction of WTX-518, a new therapeutic candidate aimed at enhancing immune responses. More data and recommended dose information for WTX-124 is expected in early 2024.
Read more →HOWLWerewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer s (SITC) 38 th Annual Meeting - Preliminar
Werewolf Therapeutics presented preliminary data from its Phase 1/1b clinical trial for WTX-124 at the SITC 38th Annual Meeting. The results indicate dose-dependent biomarker and antitumor activity in patients with advanced or metastatic solid tumors. Notably, two patients showed ongoing unconfirmed partial responses at the highest dose tested. WTX-124 was well-tolerated, with no serious dose-limiting toxicities reported, supporting its potential as a differentiated IL-2 therapy. Further data from ongoing trials are anticipated in the first half of 2024.
Read more →HOWLWerewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Werewolf Therapeutics announced that it will present clinical and preclinical data at the Society for Immunotherapy of Cancer's 38th Annual Meeting. This includes interim results from the Phase 1/1b study of WTX-124, focusing on safety and preliminary antitumor activity. Additional data from the company's PREDATOR platform and INDUKINE product candidates will also be showcased. Werewolf's lead candidate, WTX-124, demonstrates promise in the treatment of solid tumors, with no dose-limiting toxicities reported thus far.
Read more →HOWLWerewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Werewolf Therapeutics has announced the acceptance of six abstracts for poster presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting, taking place from November 1-5, 2023. The company will present interim first-in-human clinical data from the ongoing Phase 1/1b study of WTX-124, an innovative treatment for cancer. The abstracts highlight advancements in their PREDATOR platform and INDUKINE pipeline, focusing on tumor-activated treatments designed to enhance the immune response against cancer. Werewolf's commitment to advancing cancer therapeutics is underscored by their participation in this significant event.
Read more →HOWLCautionary Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, inc
Werewolf Therapeutics provided a corporate overview that includes forward-looking statements concerning its investigational drugs, WTX-124 and WTX-330, currently in Phase I clinical trials. Key focus areas include challenges with cytokine therapy, particularly around off-target toxicity, and the company's strategy to address these through advanced technology like the PREDATOR platform. The anticipated release of initial data for WTX-124 is expected in the fourth quarter of 2023, but there are significant risks associated with the development timelines, regulatory approvals, and financial stability.
Read more →HOWLWerewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124
Werewolf Therapeutics is set to host a key opinion leader (KOL) event on September 18, 2023, featuring Dr. Michael Atkins discussing the IL-2 landscape. The company will present insights on its PREDATOR™ platform and the ongoing trials for its IL-2 targeted molecule, WTX-124. This candidate is being evaluated as both a monotherapy and in combination with Pembrolizumab for patients with advanced solid tumors who have not responded to standard therapies. The event underscores Werewolf's commitment to advancing innovative cancer treatments and engaging with the scientific community.
Read more →HOWLWerewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update - Phase 1 1b clinical trial for IL-2 INDUKINE WTX-124 progressing in patients with advanced or metastatic solid tumors init
Werewolf Therapeutics reported its second quarter financial results, highlighting progress in its clinical trials for WTX-124 and WTX-330, both targeting advanced solid tumors. The company anticipates sharing important initial data from the WTX-124 trial in Q4 2023. Financially, Werewolf maintains a strong cash position, expected to last through at least the end of 2024, and reported an increase in collaboration revenue. However, the company still recorded a net loss, albeit a smaller one than the previous year.
Read more →HOWLWerewolf Therapeutics to Present at the Jefferies Healthcare Conference
Werewolf Therapeutics, an innovative biopharmaceutical company, announced that management will present an overview of the company at the Jefferies Healthcare Conference on June 8, 2023. The event will take place in New York, NY, and a live webcast will be available for interested parties. The company focuses on developing conditionally activated therapeutics that aim to enhance the immune system's ability to treat cancer. Their advanced product candidates include WTX-124 and WTX-330, aimed at solid tumors and designed to selectively activate in the tumor microenvironment.
Read more →HOWLWerewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update - Progressing Phase 1 1b clinical trial for IL-2 INDUKINE WTX-124 in advanced or metastatic solid tumors initial first-in-hu
Werewolf Therapeutics reported its Q1 2023 financial results and provided a business update, highlighting progress in its clinical trials for the IL-2 INDUKINE WTX-124 and the IL-12 INDUKINE WTX-330 candidates. The company also revealed promising early preclinical data for a third candidate, WTX-712. Financially, Werewolf's cash position improved, providing a runway for its operations through at least Q4 2024, despite a reported net loss. These developments reflect the company's ongoing commitment to advancing innovative therapies for cancer treatment.
Read more →HOWLWerewolf Therapeutics to Participate in May Investor Conferences
Werewolf Therapeutics, Inc. announced its participation in two key investor conferences in May 2023, including the Bank of America 2023 Healthcare Conference and the RBC Capital Markets Global Healthcare Conference. Management will engage in fireside chats to discuss the company's innovative therapies designed to stimulate the immune system for cancer treatment. The company leverages its proprietary PREDATOR™ platform to develop conditionally activated therapeutics aimed at improving outcomes for solid tumors. This participation is expected to bolster investor interest and enhance its market presence.
Read more →HOWLWerewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research
Werewolf Therapeutics has published preclinical data for its mWTX-330 molecule, demonstrating its ability to selectively deliver Interleukin-12 to the tumor microenvironment, inducing a strong anti-tumor immune response. The data highlights the molecule's capacity to activate and enhance tumor-infiltrating lymphocytes while minimizing toxicity associated with traditional IL-12 therapies. The company is currently recruiting patients for a Phase 1 clinical trial, further validating the potential of this innovative therapy in cancer treatment. This preclinical research signifies a promising advancement in the field of cancer immunotherapy.
Read more →HOWLWerewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update -Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from Phase 1
Werewolf Therapeutics reported its financial results for Q4 and full year 2022, highlighting significant progress in its clinical trials. The company provided updates on its lead candidates, WTX-124 and WTX-330, both of which are advancing towards initial clinical data expected in the fourth quarter of 2023. They also announced an extended cash runway through at least Q4 2024, ensuring funding for future operations. Overall, the company is demonstrating a positive trajectory in its oncology-focused therapeutic work.
Read more →HOWLWerewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023
Werewolf Therapeutics, Inc. announced a forthcoming presentation at the AACR Annual Meeting 2023, scheduled for April 14-19 in Orlando, Florida. The presentation will feature an abstract on their IL-21 INDUKINE™ molecules, which are engineered to target cancer by stimulating the immune system. The company aims to address the limitations of traditional immune therapies with their proprietary PREDATOR™ platform and has advanced candidates WTX-124 and WTX-330 into clinical stages for various tumor types.
Read more →HOWLWerewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
Werewolf Therapeutics has announced that the first patient has been dosed in its Phase 1 clinical trial for WTX-330, a novel IL-12 therapy targeting advanced solid tumors and Non-Hodgkin Lymphoma. This trial marks the second INDUKINE molecule from Waswolf’s development pipeline. The design of WTX-330 aims to enhance treatment efficacy while reducing toxic side effects commonly seen with traditional IL-12 therapies. The company is enthusiastic about the potential of this therapy to offer new options for patients facing hard-to-treat cancers.
Read more →HOWLWerewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference
Werewolf Therapeutics, Inc. will present virtually at the SVB Securities Global Biopharma Conference on February 16, 2023. Dr. Randi Isaacs, the Chief Medical Officer, will discuss the company's development of innovative cancer therapeutics using their unique PREDATOR™ platform. Their leading candidates, WTX-124 and WTX-330, aim to improve immune system responses selectively in tumors. A webcast of the presentation will be available live and archived for future viewing.
Read more →HOWLWerewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting
- mWTX-330 is designed as a systemically delivered, conditionally activated IL-12 therapy and is a member of a novel class of INDUKINE™ therapeutics - - Preclinical data supports the development of WTX-330, Werewolf’s product candidate, for the potential treatment of selected ad
Read more →HOWLWerewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update - Dosed first patient in Phase 1 1b study evaluating WTX-124 as a monotherapy and in combination with KEYTRUDA (pembrolizuma
Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update - Dosed first patient in Phase 1 1b study evaluating WTX-124 as a monotherapy and in combination with KEYTRUDA (pembrolizumab) in advanced solid tumors initial data anticipated in the
Read more →HOWLWerewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting and Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune syste
Read more →HOWLWerewolf Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
WATERTOWN, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune syst
Read more →HOWLWerewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1/1b Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid Tumors
- First clinical candidate of a new class of systemically delivered conditionally activated INDUKINE™ therapeutics developed by Werewolf - WTX-124 is designed to target delivery of a highly potent, wild-type IL-2 cytokine to the tumor microenvironment WATERTOWN, Mass., Sept. 01
Read more →HOWLWerewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights - FDA granted IND clearance for lead candidate WTX-124 for evaluation as a treatment for advanced solid tumors - - Subm
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights - FDA granted IND clearance for lead candidate WTX-124 for evaluation as a treatment for advanced solid tumors - - Submission of IND application for WTX-330 planned in 2H22 - -
Read more →HOWLWerewolf Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
WATERTOWN, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune syste
Read more →HOWLWerewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune syste
Read more →HOWLWerewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights - Entered exclusive global license and collaboration agreement with Jazz Pharmaceuticals to develop and commercialize WT
Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights - Entered exclusive global license and collaboration agreement with Jazz Pharmaceuticals to develop and commercialize WTX-613 received $15.0M upfront payment and eligibility for u
Read more →HOWLWerewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE™ Molecules at AACR 2022 Annual Meeting
WTX-124 demonstrated high tumor selectivity and generated significant anti-tumor activity in a CD8+ T cell-dependent manner WTX-330 surrogate demonstrated significant expansion of the therapeutic window, compared to recombinant IL-12, and generated potent anti-tumor immunity in
Read more →HOWLWerewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Highlights -Closed upsized IPO in May 2021 raising $120 million in gross proceeds- -Announced clinical trial co
Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Highlights -Closed upsized IPO in May 2021 raising $120 million in gross proceeds- -Announced clinical trial collaboration with Merck for WTX-124 INDUKINETM program- -R
Read more →HOWLWerewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-124 in Delivering IL-2 Selectively to the Tumor Microenvironment
CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the publication in Cancer Immunolog
Read more →HOWLWerewolf Therapeutics Announces Upcoming Presentations at AACR 2022 Annual Meeting
CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune syst
Read more →HOWLWerewolf Therapeutics to Present at the SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune syste
Read more →HOWLWerewolf Therapeutics to Present at the H.C. Wainwright Bioconnect Conference
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune syste
Read more →HOWLWerewolf Therapeutics Added to the Nasdaq Biotechnology Index
CAMBRIDGE, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune syste
Read more →HOWLWerewolf Therapeutics to Present Preclinical Data on INDUKINE™ Molecules at the 63rd American Society of Hematology (ASH) Annual Meeting
CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune syste
Read more →HOWLWerewolf Therapeutics Reports Third Quarter 2021 Financial Results and Business Update -Clinical Trial Collaboration with Merck for WTX-124 INDUKINE Program- -On Track to File Two INDs in First Half of 2022- Cambridge, M
Werewolf Therapeutics Reports Third Quarter 2021 Financial Results and Business Update -Clinical Trial Collaboration with Merck for WTX-124 INDUKINE Program- -On Track to File Two INDs in First Half of 2022- Cambridge, Mass., November 10, 2021 - Werewolf Therapeutics, Inc. (th
Read more →HOWLWerewolf Therapeutics to Present at Upcoming Conferences in November 2021
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer,
Read more →HOWLWerewolf Therapeutics Appoints Meeta Chatterjee, Ph.D., to its Board of Directors
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer,
Read more →HOWLWerewolf Therapeutics to Present Data on its INDUKINE™ Product Candidates at the Society for Immunotherapy of Cancer Annual Meeting
CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer,
Read more →HOWLWerewolf Therapeutics to Present at Upcoming Next-Gen Cytokine Therapeutics Summit
CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer
Read more →HOWLWerewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer
Read more →HOWLWerewolf Therapeutics Announces Clinical Trial Collaboration with Merck on its WTX-124 INDUKINE™ Program
CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer,
Read more →HOWLWerewolf Therapeutics Reports Second Quarter 2021 Financial Results and Business Update Cambridge, Mass.
Werewolf Therapeutics Reports Second Quarter 2021 Financial Results and Business Update Cambridge, Mass., August 12, 2021 - Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq HOWL), an innovative biopharmaceutical company pioneering the development of conditionall
Read more →HOWLWerewolf Therapeutics Announces Its Addition to the Russell 2000 Index
CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announce
Read more →HOWLWerewolf Therapeutics Appoints Chulani Karunatilake, Ph.D. as Chief Technology Officer
Veteran life sciences executive brings more than 30 years CMC and product development strategy expertise to rapidly advance programs and oversee manufacturing CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmac
Read more →HOWLWerewolf Therapeutics Reports First Quarter 2021 Financial Results - Recently completed upsized initial public offering raising $120.0 million in gross proceeds - Cambridge, Mass.
Werewolf Therapeutics Reports First Quarter 2021 Financial Results - Recently completed upsized initial public offering raising $120.0 million in gross proceeds - Cambridge, Mass., June 10, 2021 - Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ HOWL), an innov
Read more →HOWLWerewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021
CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer,
Read more →HOWLWerewolf Therapeutics Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer
Read more →Competitive Position
How HOWL ranks across every disease it competes inCompetitive Position is a premium feature
See how HOWL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial